Biohaven Return on Tangible Equity 2016-2023 | BHVN

Current and historical return on tangible equity values for Biohaven (BHVN) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Biohaven Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2023-03-31 $-0.54B $0.45B -1277.65%
2022-12-31 $-0.57B $0.52B 283.58%
2022-09-30 $-0.29B $0.08B 88.99%
2022-06-30 $-0.28B $-0.88B 54.22%
2022-03-31 $-0.05B $-0.52B 11.02%
2021-12-31 $-0.21B $0.02B 57.72%
2021-09-30 $-0.10B $-0.65B 20.74%
2021-06-30 $-0.24B $-0.51B 62.80%
2021-03-31 $-0.21B $-0.34B 76.94%
2020-12-31 $-0.12B $-0.43B 70.00%
2020-09-30 $-0.70B $-0.25B 464.56%
2020-06-30 $-0.61B $-0.08B 1068.42%
2020-03-31 $-0.64B $0.08B -7302.86%
2019-12-31 $-0.53B $-0.35B -4141.18%
2019-09-30 $-0.43B $0.12B -313.36%
2019-06-30 $-0.39B $0.19B -310.58%
2019-03-31 $-0.22B $0.10B -200.46%
2018-12-31 $-0.24B $0.15B -216.22%
2018-09-30 $-0.21B $0.07B -199.53%
2018-06-30 $-0.19B $0.12B -150.68%
2018-03-31 $-0.20B $0.11B -136.50%
2017-12-31 $-0.14B $0.13B -110.98%
2017-09-30 $-0.14B $0.16B -150.41%
2017-06-30 $-0.12B $0.19B -233.18%
2017-03-31 $-0.08B $0.02B -1866.67%
2016-12-31 $-0.06B $-0.00B 12800.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.059B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.076B 8.19
GSK (GSK) United Kingdom $70.106B 9.78
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.491B 22.15
Ginkgo Bioworks Holdings (DNA) United States $3.170B 0.00
Arcus Biosciences (RCUS) United States $1.611B 0.00
Emergent Biosolutions (EBS) United States $0.412B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.175B 0.00
Enzo Biochem (ENZ) United States $0.114B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00